GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget by $1.1 billion and cut its 2024 sales outlook.

Respiratory virus season is quickly approaching, meaning we will start to see cold, flu, COVID, and RSV in our community. The ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

Covid-19 cases are high in many parts of the U.S. and they’re continuing to rise. These numbers come as flu season is coming ...

“Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season ... dose of flu vaccine each year. But some children ...